A study to assess the knowledge on hypoglycemia among the diabetic patient in selected hospital, Siliguri

Background:The prevalence of diabetes mellitus, is a major health concern that affects people around the world, and is increasing yearly. When blood glucose levels go below normal, a condition known as hypoglycemia, an immediate consequence of diabetes mellitus, occurs. The International Diabetes Federation reported thatthere were 451 million diabetics globally in 2017 and by 2045, it is anticipated that there will be 693 million. The objective of this study was to assess the level of knowledge of diabetic patient regarding hypoglycaemia and to find out the association between the levels of knowledge of diabetic patient on hypoglycaemia with their selected demographic variable.Methods:A descriptive cross-sectional study, was carried out in the month of June 2022. A semi-structured questionnaire was used to interview 100 study participants who were diabetes patients who had been admitted to the medical ward and who had visited the endocrinology outpatient department.Results:52% of the samples had fair knowledge on hypoglycemia, while 23% of them had poor knowledge. Demographic variable such as age, income, treatment, frequency of taking medicine, experience of symptoms of hypoglycemia and dietary habit were statistically significant with the level of knowledge, p<0.05.Conclusions:The study's findings highlighted the fact that most diabetes mellitus patients had a fair understanding of hypoglycemia. The health care personnel should also take time and efforts to educate patients about the sign of hypoglycemia. So that hypoglycemic episodes and morbidity could be reduced or prevented at primordial level.

Effect of oral antidiabetic drugs on NGF mRNA expr（e）ssion in rats brain with diabetes / 重庆医学

Objective To observe the expression of NGF mRNA in rats brain with diabetes and the effects of hypoglycemia caused by oral antidiabetic drugs on NGF mRNA.Methods A total of 64 adult Wistar rats were randomly divided into control group(16)and diabetes model group(48).Using high fat and high sugar diet+intraperitoneal injection of streptozotocin to prepare type 2 diabetes model.The diabetes model group was randomly divided into non-medication group(16),oral medication group (16) and hypoglycemia group(16).The oral medication rats and hypoglycemia rats were given glibenclamide+metformin by intragastric administration once daily for 12 d,the dose of hypoglycemia rats was 5 times of treatment rats.The brain tissues of rats in each group were used respectively the RT-PCR method to detect NGF mRNA at 3,6,9 and 12 d.Results Compared with the control group,the expression of NGF mRNA in the brain tissues of the 3 groups of diabetic rats were decreased in different degrees and the non-medication group was the most obvious(P＜0.01).Compared with the non-medication group,the oral medication group was significantly increased(P＜0.01),the hypoglycemia group was further decreased(P＜ 0.01).Conclusion Oral hypoglycemic drugs can effectively enhance the expression of NGF mRNA in brain tissue of diabetic rats,but hypoglycemia caused by Oral antidiabetic drugs can make the expression of NGF mRNA further decreased.So hypoglycemia is not conducive to the repair of diabetic neuropathy.

Application Analysis of Oral Hypoglycemic Drugs in 34 Hospitals of Nanjing during 2011-2013 / 中国药师

Objective:To evaluate the utilization of oral hypoglycemic drugs in 34 hospitals of Nanjing to provide clinical reference for the drug rational use. Methods: According to the sales data of oral hypoglycemic drugs in 34 hospitals of Nanjing from 2011 to 2013,the utilization of oral hypoglycemic drugs was analyzed retrospectively in respect of consumption sum,DDDs and defined daily cost ( DDC) by daily dose limit analysis method. Results: The top 3 oral hypoglycemic drugs in the list of consumption sum were acarbose,glimepiride and metformin. In terms of DDDs,glimepiride, metformin and gliclazide ranked the top 3. The consumption sum and DDDs of oral hypoglycemic drugs were increased year by year in Nanjing. The ratio of serial number of consumption sum and DDDs was from 0. 3 to 2. 0. Conclusion: The demanded quantity of oral hypoglycemic drugs is increased year by year from 2011 to 2013. The application conforms to the safe, effective and economic principle. The drugs should be chosen according to the drug characteristics in order to improve the abnormal glucose metabolism and prevent and treat the complications.

Comparison of Insulin Glargine with Human Premix Insulin in Patients with Type 2 Diabetes Inadequately Controlled on Oral Hypoglycemic Drugs in a 24-week Randomized Study among Central Indian Population.

Objective: To compare the safety and efficacy of the long-acting analog insulin glargine and human premix insulin in patients with type 2 diabetes who were previously treated with oral hypoglycemic drugs alone but inadequately controlled. Research design and methods: A total of 750 subjects with type 2 diabetes who were receiving oral hypoglycemic drugs for diabetes control were randomized to receive insulin glargine once-daily (n = 370) or human premix insulin twice-daily (n = 380) for 24 weeks in an open-label, tertiary center study. Doses were adjusted systematically to obtain target fasting glucose <100 mg/dl. Outcomes included fasting blood sugar, glycosyloted hemoglobin (HbA1C) levels, change in weight and insulin dose from study start to end. Results: At the start of study, age range was 30-70 years, BMI was 26.48 ± 6.3 kg/m2 and HbA1C was 11.9 ± 3.1% (mean ± SD) for both groups. The mean change (means ± SD) in HbA1C from baseline to endpoint was similar in the insulin glargine group (−3.0 ± 1.68%) and the human premix insulin group (−2.89 ± 1.79%) (p = 0.3861). The symptomatic hypoglycemic episodes were greater with human premix insulin than with glargine (significance level 0.00002). Subjects in the insulin glargine group experienced less weight gain than those in the premix human insulin group (0.4 vs 1.4 kg, p < 0.0001). Conclusions: In patients with type 2 diabetes, once-daily bedtime insulin glargine is as effective as twice-daily human premix insulin in improving and maintaining glycemia control. In addition, insulin glargine demonstrates a lower risk of symptomatic hypoglycemia and less weight gain compared with human premix insulin. The treatments were associated with similar reductions in fasting glucose levels and HbA1C levels.

Analysis on Use of Oral Hypoglycemic Drugs in Our Hospital from 2001 to 2003 / 中国药房

OBJECTIVE: To evaluate the use of oral hypoglycemic drugs in our hospital in order to provide an reference for rational use of drugs in clinic. METHODS: DDDs, sales volume, and daily expenses of drugs in our hospital from 2001to 2003 were analyzed with the method of DDD analysis. RESULTS: The varieties, quantities and sales volumes of oral hypoglycemic drugs increased year by year. The top 3 hypoglycemic drugs in respect of DDDs were dimethylbigmide, gliclazide, and glipizide. The top 3 hypoglycemic drugs in respect of sales volume were glipizide, acarbose, and dimethylbimide. The ratio of sales volume sequencing to that of DDDs was between 0.2～4. CONCLUSIONS: Gliclazide and dimethylbimide are most widely used and their prices are reasonable; Acarbose is expensive, and its sales volume has not grown in pace with DDDs.